Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ADEPT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 108 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Tietze, LF; Herzig, T; Fecher, A; Haunert, F; Schuberth, I
      Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues forantibody-directed enzyme tumor therapy

      CHEMBIOCHEM
    2. Damen, EWP; de Groot, FMH; Scheeren, HW
      Novel anthracycline prodrugs

      EXPERT OPINION ON THERAPEUTIC PATENTS
    3. Rafii, F; Hehman, G; Lunsford, P
      Purification and characterization of an enzyme from Mycobacterium sp Pyr-1, with nitroreductase activity and an N-terminal sequence similar to lipoamide dehydrogenase

      ARCHIVES OF MICROBIOLOGY
    4. Rogozin, V; Edan, Y; Flash, T
      A real-time trajectory modification algorithm

      ROBOTICA
    5. Denny, WA
      Prodrug strategies in cancer therapy

      EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    6. Monneret, C
      Recent developments in the field of antitumour anthracyclines

      EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    7. Bloss, R
      Adept focuses on acquisitions to secure new markets

      INDUSTRIAL ROBOT
    8. Shabat, D; Lode, HN; Pertl, U; Reisfeld, RA; Rader, C; Lerner, RA; Barbas, CF
      In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    9. Chen, BM; Cheng, TL; Tzou, SC; Roffler, SR
      Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy

      INTERNATIONAL JOURNAL OF CANCER
    10. Houba, PHJ; Boven, E; van der Meulen-Muileman, IH; Leenders, RGG; Scheeren, JW; Pinedo, HM; Haisma, HJ
      Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate

      INTERNATIONAL JOURNAL OF CANCER
    11. Azoulay, M; Chalard, F; Gesson, JP; Florent, JC; Monneret, C
      2-nitro and 4-nitro-quinone-methides are not irreversible inhibitors of bovine beta-glucuronidase

      CARBOHYDRATE RESEARCH
    12. Satchi, R; Connors, TA; Duncan, R
      PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsinB and PK1 as a model combination

      BRITISH JOURNAL OF CANCER
    13. Webley, SD; Francis, RJ; Pedley, RB; Sharma, SK; Begent, RHJ; Hartley, JA; Hochhauser, D
      Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material

      BRITISH JOURNAL OF CANCER
    14. Folkes, LK; Wardman, P
      Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy

      BIOCHEMICAL PHARMACOLOGY
    15. Nivinskas, H; Koder, RL; Anusevicius, Z; Sarlauskas, J; Miller, AF; Cenas, N
      Quantitative structure-activity relationships in two-electron reduction ofnitroaromatic compounds by Enterobacter cloacae NAD(P)H : nitroreductase

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    16. Burke, PJ
      The potential use of carboxypeptidase G(2) in the treatment of cancer

      EXPERT OPINION ON THERAPEUTIC PATENTS
    17. Napier, MP; Sharma, SK; Springer, CJ; Bagshawe, KD; Green, AJ; Martin, J; Stribbling, SM; Cushen, N; O'Malley, D; Begent, RHJ
      Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of actionin colorectal carcinoma

      CLINICAL CANCER RESEARCH
    18. Hu, LQ; Liu, B; Hacking, DR
      5 '-[2-(2-nitrophenyl)-2-methylpropionyl]-2 '-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: Synthesis, stability andreductive activation

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    19. Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DIR; Cooke, SP; Flynn, AA; Sharma, SK; Boxer, G; Pedley, RB; Begent, RHJ
      Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    20. Sykes, BM; Hay, MP; Bohinc-Herceg, D; Helsby, NA; O'Connor, CJ; Denny, WA
      Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates

      JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    21. Chester, KA; Bhatia, J; Boxer, G; Cooke, SP; Flynn, AA; Huhalov, A; Mayer, A; Pedley, RB; Robson, L; Sharma, SK; Spencer, DIR; Begent, RHJ
      Clinical applications of phage-derived sFvs and sFv fusion proteins

      DISEASE MARKERS
    22. Parkinson, GN; Skelly, JV; Neidle, S
      Crystal structure of FMN-dependent nitroreductase from Escherichia coli B:A prodrug-activating enzyme

      JOURNAL OF MEDICINAL CHEMISTRY
    23. Monks, NR; Calvete, JA; Curtin, NJ; Blakey, DC; East, SJ; Newell, DR
      Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

      BRITISH JOURNAL OF CANCER
    24. Leenders, RGG; Damen, EWP; Bijsterveld, EJA; Scheeren, HW; Houba, PHJ; van der Meulen-Muileman, IH; Boven, E; Haisma, HJ
      Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy

      BIOORGANIC & MEDICINAL CHEMISTRY
    25. Hay, MP; Sykes, BM; Denny, WA; Wilson, WR
      A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    26. Hay, MP; Sykes, BM; Denny, WA; O'Connor, CJ
      Substituent effects on the kinetics of reductively-initiated fragmentationof nitrobenzyl carbamates designed as triggers for bioreductive prodrugs

      JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    27. Madec-Lougerstay, R; Florent, JC; Monneret, C
      Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy

      JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    28. Bakina, E; Farquhar, D
      Intensely cytotoxic anthracycline prodrugs: galactosides

      ANTI-CANCER DRUG DESIGN
    29. Niculescu-Duvaz, I; Friedlos, F; Niculescu-Duvaz, D; Davies, L; Springer, CJ
      Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)

      ANTI-CANCER DRUG DESIGN
    30. Desbene, S; Van, HDT; Michel, S; Tillequin, F; Koch, M; Schmidt, F; Florent, JC; Monneret, C; Straub, R; Czech, J; Gerken, M; Bosslet, K
      Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy

      ANTI-CANCER DRUG DESIGN
    31. Dubowchik, GM; Walker, MA
      Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

      PHARMACOLOGY & THERAPEUTICS
    32. Papot, S; Bachmann, C; Combaud, D; Gesson, JP
      Study of biscarbamates derived from 2-aminobenzylamines as models for alcohol prodrugs

      TETRAHEDRON
    33. Smyth, TP; O'Connor, MJ; O'Donnell, ME
      Extending the beta-lactamase-dependent prodrug armory: S-aminosulfeniminocephalosporins as dual-release prodrugs

      JOURNAL OF ORGANIC CHEMISTRY
    34. Khan, TH; Eno-Amooquaye, EA; Searle, F; Browne, PJ; Osborn, HMI; Burke, PJ
      Novel inhibitors of carboxypeptidase G(2) (CPG(2)): Potential use in antibody-directed enzyme prodrug therapy

      JOURNAL OF MEDICINAL CHEMISTRY
    35. Mayer, A; Chester, KA; Flynn, AA; Begent, RHJ
      Taking engineered anti-CEA antibodies to the clinic

      JOURNAL OF IMMUNOLOGICAL METHODS
    36. Cheng, TL; Chou, WC; Chen, BM; Chern, JW; Roffler, SR
      Characterization of an antineoplastic glucuronide prodrug

      BIOCHEMICAL PHARMACOLOGY
    37. Fonseca, MJ; Haisma, HJ; Klaasen, S; Vingerhoeds, MH; Storm, G
      Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties

      BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
    38. SCHMIDT F; FLORENT JC; MONNERET C
      SYNTHESIS AND STUDY OF A DIPYRIDAMOLE PRODRUG - APPLICATION OF THE ADEPT STRATEGY TO THE MDR RESISTANCE IN CANCER-CHEMOTHERAPY

      COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE II FASCICULE C-CHIMIE
    39. KODER RL; MILLER AF
      OVEREXPRESSION, ISOTOPIC LABELING, AND SPECTRAL CHARACTERIZATION OF ENEROBACTER-CLOACAE NITROREDUCTASE

      Protein expression and purification
    40. FOLKES LK; CANDEIAS LP; WARDMAN P
      TOWARD TARGETED OXIDATION THERAPY OF CANCER - PEROXIDASE-CATALYZED CYTOTOXICITY OF INDOLE-3-ACETIC ACIDS

      International journal of radiation oncology, biology, physics
    41. HAISMA HJ; BRAKENHOFF RH; VANDERMEULENMUILEMAN I; PINEDO HM; BOVEN E
      CONSTRUCTION AND CHARACTERIZATION OF A FUSION PROTEIN OF SINGLE-CHAINANTI-CARCINOMA ANTIBODY 323 A3 AND HUMAN BETA-GLUCURONIDASE/

      Cancer immunology and immunotherapy
    42. Desbene, S; Van, HDT; Michel, S; Koch, M; Tillequin, F; Fournier, G; Farjaudon, N; Monneret, C
      Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation

      ANTI-CANCER DRUG DESIGN
    43. Lougerstay-Madec, R; Florent, JC; Monneret, C; Nemati, F; Poupon, MF
      Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard

      ANTI-CANCER DRUG DESIGN
    44. KODER RL; MILLER AF
      STEADY-STATE KINETIC MECHANISM, STEREOSPECIFICITY, SUBSTRATE AND INHIBITOR SPECIFICITY OF ENTEROBACTER-CLOACAE NITROREDUCTASE

      Biochimica et biophysica acta. Protein structure and molecular enzymology
    45. Blackburn, GM; Datta, A; Denham, H; Wentworth, P
      Catalytic antibodies

      ADVANCES IN PHYSICAL ORGANIC CHEMISTRY, VOL 31
    46. Denny, WA; Wilson, WR
      The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies

      JOURNAL OF PHARMACY AND PHARMACOLOGY
    47. SVENSSON HP; FRANK IS; BERRY KK; SENTER PD
      THERAPEUTIC EFFECTS OF MONOCLONAL ANTIBODY-BETA-LACTAMASE CONJUGATES IN COMBINATION WITH A NITROGEN-MUSTARD ANTICANCER PRODRUG IN MODELS OFHUMAN RENAL-CELL CARCINOMA

      Journal of medicinal chemistry
    48. FLORENT JC; DONG X; GAUDEL G; MITAKU S; MONNERET C; GESSON JP; JACQUESY JC; MONDON M; RENOUX B; ANDRIANOMENJANAHARY S; MICHEL S; KOCH M; TILLEQUIN F; GERKEN M; CZECH J; STRAUB R; BOSSLET K
      PRODRUGS OF ANTHRACYCLINES FOR USE IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY

      Journal of medicinal chemistry
    49. Niculescu-Duvaz, D; Niculescu-Duvaz, I; Friedlos, F; Martin, J; Spooner, R; Davies, L; Marais, R; Springer, CJ
      Self-immolative nitrogen mustard prodrugs for suicide gene therapy

      JOURNAL OF MEDICINAL CHEMISTRY
    50. BLAKEY D
      ENZYME PRODRUG THERAPY OF CANCER

      Expert opinion on therapeutic patents
    51. GUSTERSON B; CUI W; IWOBI M; CROMPTON MR; HAROLD G; HOBBS S; KAMALATI T; KNOX R; NEIL C; YULL F; HOWARD B; CLARK AJ
      SELECTIVE CELL ABLATION IN THE MAMMARY-GLAND OF TRANSGENIC MICE

      Endocrine-related cancer
    52. SIEMERS NO; KERR DE; YARNOLD S; STEBBINS MR; VRUDHULA VM; HELLSTROM I; HELLSTROM KE; SENTER PD
      CONSTRUCTION, EXPRESSION, AND ACTIVITIES OF L49-SFV-BETA-LACTAMASE, ASINGLE-CHAIN ANTIBODY FUSION PROTEIN FOR ANTICANCER PRODRUG ACTIVATION

      Bioconjugate chemistry
    53. LEMMON MJ; VANZIJL P; FOX ME; MAUCHLINE ML; GIACCIA AJ; MINTON NP; BROWN JM
      ANAEROBIC-BACTERIA AS A GENE DELIVERY SYSTEM THAT IS CONTROLLED BY THE TUMOR MICROENVIRONMENT

      Gene therapy
    54. DRABEK D; GUY J; CRAIG R; GROSVELD F
      THE EXPRESSION OF BACTERIAL NITROREDUCTASE IN TRANSGENIC MICE RESULTSIN SPECIFIC CELL-KILLING BY THE PRODRUG CB1954

      Gene therapy
    55. CLARK AJ; IWOBI M; CUI W; CROMPTON M; HAROLD G; HOBBS S; KAMALATI T; KNOX R; NEIL C; YULL F; GUSTERSON B
      SELECTIVE CELL ABLATION IN TRANSGENIC MICE EXPRESSING ESCHERICHIA-COLI NITROREDUCTASE

      Gene therapy
    56. SIIM BG; DENNY WA; WILSON WR
      NITRO REDUCTION AS AN ELECTRONIC SWITCH FOR BIOREDUCTIVE DRUG ACTIVATION

      Oncology research
    57. LEE M; SIMPSON JE; WOO S; KAENZIG C; ANLEZARK GM; ENOAMOOQUAYE E; BURKE PJ
      SYNTHESIS OF AN AMINOPROPYL, ANALOG OF THE EXPERIMENTAL ANTICANCER DRUG TALLIMUSTINE, AND ACTIVATION OF ITS 4-NITROBENZYLCARBAMOYL PRODRUG BY NITROREDUCTASE AND NADH

      Bioorganic & medicinal chemistry letters
    58. GREEN NK; YOUNGS DJ; NEOPTOLEMOS JP; FRIEDLOS F; KNOX RJ; SPRINGER CJ; ANLEZARK GM; MICHAEL NP; MELTON RG; FORD MJ; YOUNG LS; KERR DJ; SEARLE PF
      SENSITIZATION OF COLORECTAL AND PANCREATIC-CANCER CELL-LINES TO THE PRODRUG 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) BY RETROVIRAL TRANSDUCTION AND EXPRESSION OF THE ESCHERICHIA-COLI NITROREDUCTASE GENE

      Cancer gene therapy
    59. STRIBBLING SM; MARTIN J; PEDLEY RB; BODEN JA; SHARMA SK; SPRINGER CJ
      BIODISTRIBUTION OF AN ANTIBODY-ENZYME CONJUGATE FOR ANTIBODY-DIRECTEDENZYME PRODRUG THERAPY IN NUDE-MICE BEARING A HUMAN COLON ADENOCARCINOMA XENOGRAFT

      Cancer chemotherapy and pharmacology
    60. MARTIN J; STRIBBLING SM; POON GK; BEGENT RHJ; NAPIER M; SHARMA SK; SPRINGER CJ
      ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY - PHARMACOKINETICS AND PLASMA-LEVELS OF PRODRUG AND DRUG IN A PHASE-I CLINICAL-TRIAL

      Cancer chemotherapy and pharmacology
    61. ER MJ; LIEW KC
      CONTROL OF ADEPT-ONE SCARA ROBOT USING NEURAL NETWORKS

      IEEE transactions on industrial electronics
    62. NICULESCUDUVAZ I; SPRINGER CJ
      ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - A REVIEW

      Advanced drug delivery reviews
    63. STORM G; VINGERHOEDS MH; CROMMELIN DJA; HAISMA HJ
      IMMUNOLIPOSOMES BEARING ENZYMES (IMMUNO-ENZYMOSOMES) FOR SITE-SPECIFIC ACTIVATION OF ANTICANCER PRODRUGS

      Advanced drug delivery reviews
    64. RETTA BME; BURKE PJ; PHOTIOU A; MELTON RG; ENOAMOOQUAYE E
      ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - EVIDENCE FOR A BYSTANDER EFFECT IN-VITRO

      International journal of oncology
    65. BAILEY SM; KNOX RJ; HOBBS SM; JENKINS TC; MAUGER AB; MELTON RG; BURKE PJ; CONNORS TA; HART IR
      INVESTIGATION OF ALTERNATIVE PRODRUGS FOR USE WITH ESCHERICHIA-COLI NITROREDUCTASE IN SUICIDE GENE APPROACHES TO CANCER-THERAPY

      Gene therapy
    66. TERCEL M; DENNY WA; WILSON WR
      A NOVEL NITROSUBSTITUTED SECO-CI - APPLICATION AS A REDUCTIVELY ACTIVATED ADEPT PRODRUG

      Bioorganic & medicinal chemistry letters
    67. CONNORS TA
      IS THERE A FUTURE FOR CANCER-CHEMOTHERAPY - THE CLAVEL,MICHEL LECTURE

      Annals of oncology
    68. VINGERHOEDS MH; HAISMA HJ; BELLIOT SO; SMIT RHP; CROMMELIN DJA; STORM G
      IMMUNOLIPOSOMES AS ENZYME-CARRIERS (IMMUNO-ENZYMOSOMES) FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - OPTIMIZATION OF PRODRUG ACTIVATING CAPACITY

      Pharmaceutical research
    69. SPRINGER CJ; BAVETSIAS V; JACKMAN AL; BOYLE FT; MARSHALL D; PEDLEY RB; BISSET GMF
      PRODRUGS OF THYMIDYLATE SYNTHASE INHIBITORS - POTENTIAL FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)

      Anti-cancer drug design
    70. ATWELL GJ; BOYD M; PALMER BD; ANDERSON RF; PULLEN SM; WILSON WR; DENNY WA
      SYNTHESIS AND EVALUATION OF 4-SUBSTITUTED ANALOGS OF 5-[N,N-BIS(2-CHLOROETHYL)AMINO]2-NITROBENZAMIDE AS BIOREDUCTIVELY ACTIVATED PRODRUGS USING AN ESCHERICHIA-COLI NITROREDUCTASE

      Anti-cancer drug design
    71. SHERWOOD RF
      ADVANCED DRUG-DELIVERY REVIEWS - ENZYME PRODRUG THERAPY

      Advanced drug delivery reviews
    72. MELTON RG
      PREPARATION AND PURIFICATION OF ANTIBODY-ENZYME CONJUGATES FOR THERAPEUTIC APPLICATIONS

      Advanced drug delivery reviews
    73. CHESTER KA; HAWKINS RE
      OPPORTUNITIES WITH PHAGE TECHNOLOGY AND ANTIBODY ENGINEERING OF FUSION PROTEINS

      Advanced drug delivery reviews
    74. SHARMA SK
      ACCELERATED CLEARANCE SYSTEMS

      Advanced drug delivery reviews
    75. BEGENT RHJ; BAGSHAWE KD
      BIODISTRIBUTION STUDIES

      Advanced drug delivery reviews
    76. BURKE PJ
      ALKYLATING AGENT PRODRUGS FOR ADEPT

      Advanced drug delivery reviews
    77. SHARMA SK
      IMMUNE-RESPONSE IN ADEPT

      Advanced drug delivery reviews
    78. KEARNEY AS
      PRODRUGS AND TARGETED DRUG-DELIVERY

      Advanced drug delivery reviews
    79. SINHABABU AK; THAKKER DR
      PRODRUGS OF ANTICANCER AGENTS

      Advanced drug delivery reviews
    80. SCHUMACHER U; ADAM E; ZANGEMEISTERWITTKE U; GOSSRAU R
      HISTOCHEMISTRY OF THERAPEUTICALLY RELEVANT ENZYMES IN HUMAN TUMORS TRANSPLANTED INTO SEVERE COMBINED IMMUNODEFICIENT (SCID) MICE - NITRIC-OXIDE SYNTHASE - ASSOCIATED DIAPHORASE, BETA-D-GLUCURONIDASE AND NONSPECIFIC ALKALINE-PHOSPHATASE

      Acta histochemica
    81. SHARMA SK; BAGSHAWE KD; MELTON RG; BEGENT RHJ
      EFFECT OF CYCLOSPORINE ON IMMUNOGENICITY OF A BACTERIAL ENZYME CARBOXYPEPTIDASE G2 IN ADEPT

      Transplantation proceedings
    82. LARDEN DW; CHEUNG HTA
      SYNTHESIS OF N-ALPHA-AMINOACYL DERIVATIVES OF MELPHALAN FOR POTENTIALUSE IN DRUG TARGETING

      Tetrahedron letters
    83. LEENDERS RGG; RUYTENBEEK R; DAMEN EWP; SCHEEREN HW
      HIGHLY DIASTEREOSELECTIVE SYNTHESIS OF ANOMERIC BETA-O-GLYCOPYRANOSYLCARBAMATES FROM ISOCYANATES

      Synthesis
    84. DOWELL RI; SPRINGER CJ; DAVIES DH; HADLEY EM; BURKE PJ; BOYLE FT; MELTON RG; CONNORS TA; BLAKEY DC; MAUGER AB
      NEW MUSTARD PRODRUGS FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY - ALTERNATIVES TO THE AMIDE LINK

      Journal of medicinal chemistry
    85. BLAKEY DC; BURKE PJ; DAVIES DH; DOWELL RI; EAST SJ; ECKERSLEY KP; FITTON JE; MCDAID J; MELTON RG; NICULESCUDUVAZ IA; PINDER PE; SHARMA SK; WRIGHT AF; SPRINGER CJ
      ZD2767, AN IMPROVED SYSTEM FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY THAT RESULTS IN TUMOR REGRESSIONS IN COLORECTAL TUMOR XENOGRAFTS

      Cancer research
    86. DENNY WA; WILSON WR; HAY MP
      RECENT DEVELOPMENTS IN THE DESIGN OF BIOREDUCTIVE DRUGS

      British Journal of Cancer
    87. HOUBA PHJ; LEENDERS RGG; BOVEN E; SCHEEREN JW; PINEDO HM; HAISMA HJ
      CHARACTERIZATION OF NOVEL ANTHRACYCLINE PRODRUGS ACTIVATED BY HUMAN BETA-GLUCURONIDASE FOR USE IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY

      Biochemical pharmacology
    88. RODRIGUES ML; CARTER P; WIRTH C; MULLINS S; LEE A; BLACKBURN BK
      SYNTHESIS AND BETA-LACTAMASE-MEDIATED ACTIVATION OF A CEPHALOSPORIN-TAXOL PRODRUG

      Chemistry & biology
    89. CONNORS TA; KNOX RJ
      PRODRUGS IN CANCER-CHEMOTHERAPY

      Stem cells
    90. DEONARAIN MP; SPOONER RA; EPENETOS AA
      GENETIC DELIVERY OF ENZYMES FOR CANCER-THERAPY

      Gene therapy
    91. CONNORS TA
      THE CHOICE OF PRODRUGS FOR GENE DIRECTED ENZYME PRODRUG THERAPY OF CANCER

      Gene therapy
    92. SPRINGER CJ; NICULESCUDUVAZ I
      ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) WITH MUSTARD PRODRUGS

      Anti-cancer drug design
    93. MURRAY JC; CARMICHAEL J
      TARGETING SOLID TUMORS - CHALLENGES, DISAPPOINTMENTS, AND OPPORTUNITIES

      Advanced drug delivery reviews
    94. MINTON NP; MAUCHLINE ML; LEMMON MJ; BREHM JK; FOX M; MICHAEL NP; GIACCIA A; BROWN JM
      CHEMOTHERAPEUTIC TUMOR TARGETING USING CLOSTRIDIAL SPORES

      FEMS microbiology reviews
    95. ROGERS GT; BURKE PJ; SHARMA SK; KOODIE R; BODEN JA
      PLASMA-CLEARANCE OF AN ANTIBODY-ENZYME CONJUGATE IN ADEPT BY MONOCLONAL ANTI-ENZYME - ITS EFFECT ON PRODRUG ACTIVATION IN-VIVO

      British Journal of Cancer
    96. BLAKEY DC; DAVIES DH; DOWELL RI; EAST SJ; BURKE PJ; SHARMA SK; SPRINGER CJ; MAUGER AB; MELTON RG
      ANTITUMOR EFFECTS OF AN ANTIBODY-CARBOXYPEPTIDASE G2 CONJUGATE IN COMBINATION WITH PHENOL MUSTARD PRODRUGS

      British Journal of Cancer
    97. ANLEZARK GM; MELTON RG; SHERWOOD RF; WILSON WR; DENNY WA; PALMER BD; KNOX RJ; FRIEDLOS F; WILLIAMS A
      BIOACTIVATION OF DINITROBENZAMIDE MUSTARDS BY AN ESCHERICHIA-COLI-B NITROREDUCTASE

      Biochemical pharmacology
    98. SVENSSON HP; WALLACE PM; SENTER PD
      SYNTHESIS AND CHARACTERIZATION OF MONOCLONAL ANTIBODY-BETA-LACTAMASE CONJUGATES

      Bioconjugate chemistry
    99. BAGSHAWE KD; SHARMA SK; SPRINGER CJ; ROGERS GT
      ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - REVIEW

      Annals of oncology
    100. MICHAEL NP; BREHM JK; ANLEZARK GM; MINTON NP
      PHYSICAL CHARACTERIZATION OF THE ESCHERICHIA-COLI-B GENE ENCODING NITROREDUCTASE AND ITS OVER-EXPRESSION IN ESCHERICHIA-COLI K12

      FEMS microbiology letters


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/01/21 alle ore 21:58:05